Presentation is loading. Please wait.

Presentation is loading. Please wait.

INT-767 treatment prevents the increase in renal HIF and Glut1 expression and ER stress in diabetic DBA/2J mice. INT-767 treatment prevents the increase.

Published byEeva-Liisa Hyttinen Modified over 6 years ago

Similar presentations

Presentation on theme: "INT-767 treatment prevents the increase in renal HIF and Glut1 expression and ER stress in diabetic DBA/2J mice. INT-767 treatment prevents the increase."— Presentation transcript:

1 INT-767 treatment prevents the increase in renal HIF and Glut1 expression and ER stress in diabetic DBA/2J mice. INT-767 treatment prevents the increase in renal HIF and Glut1 expression and ER stress in diabetic DBA/2J mice. (A) HIF-1α and HIF-2α mRNA expression is increased in the diabetic kidney, which is prevented by INT-767. (B) Glut1 protein is increased in the diabetic kidney, which is prevented by INT-767. (C) INT-767 treatment prevents the increase in renal ER stress in diabetic DBA/2J mice as determined by phospho–EIF-2α versus total EIF-2α protein abundance. CON, nondiabetic DBA/2J; STZ, diabetic DBA/2J without treatment; STZ/INT-767, diabetic DBA/2J treated with INT-767. *P<0.05 versus CON (n=6 mice per group); †P<0.05 versus STZ (n=6 mice per group). Xiaoxin X. Wang et al. JASN 2018;29: ©2018 by American Society of Nephrology

Download ppt "INT-767 treatment prevents the increase in renal HIF and Glut1 expression and ER stress in diabetic DBA/2J mice. INT-767 treatment prevents the increase."

Similar presentations

Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in the adriamycin (ADRIA)–induced nephropathy rat model for FSGS. ADRIA-induced.

Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in the adriamycin (ADRIA)–induced nephropathy rat model for FSGS. ADRIA-induced.
PDE5A is expressed by podocytes.

PDE5A is expressed by podocytes.
Inhibition of ILK by QLT-0267 suppresses type I and type III collagen expression and ameliorates interstitial collagen deposition and renal fibrosis after.

Inhibition of ILK by QLT-0267 suppresses type I and type III collagen expression and ameliorates interstitial collagen deposition and renal fibrosis after.
Inhibition of ILK by QLT-0267 reduces β-catenin accumulation and inhibits Snail1 expression in obstructive nephropathy. Inhibition of ILK by QLT-0267 reduces.

Inhibition of ILK by QLT-0267 reduces β-catenin accumulation and inhibits Snail1 expression in obstructive nephropathy. Inhibition of ILK by QLT-0267 reduces.
Sildenafil does not prevent TRPC6 overexpression and podocyte injury in adriamycin (ADRIA)–challenged podocyte-specific PPAR-γ KO mice. Sildenafil does.

Sildenafil does not prevent TRPC6 overexpression and podocyte injury in adriamycin (ADRIA)–challenged podocyte-specific PPAR-γ KO mice. Sildenafil does.
TGF-β1 induces ILK activity in renal tubular epithelial cells.

TGF-β1 induces ILK activity in renal tubular epithelial cells.
Relationship between urinary TNF-α and RANTES excretion

Relationship between urinary TNF-α and RANTES excretion
Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.

Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.
Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6 expression. Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6.

Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6 expression. Podocyte-specific PPAR-γ–deficient mice show increased glomerular TRPC6.
Inhibition of ILK activity does not affect normal kidney structure and nephrin/ILK interaction in vivo. Inhibition of ILK activity does not affect normal.

Inhibition of ILK activity does not affect normal kidney structure and nephrin/ILK interaction in vivo. Inhibition of ILK activity does not affect normal.
Inhibition of ILK by QLT-0267 abrogates PAI-1 and MMP-2 induction by TGF-β1 in tubular epithelial cells. Inhibition of ILK by QLT-0267 abrogates PAI-1.

Inhibition of ILK by QLT-0267 abrogates PAI-1 and MMP-2 induction by TGF-β1 in tubular epithelial cells. Inhibition of ILK by QLT-0267 abrogates PAI-1.
Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.

Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.
Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF

Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF
Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.

Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.
Schematic representations of DGKE protein and mRNA illustrating the relative positions of all pathogenic mutations reported to date. Schematic representations.

Schematic representations of DGKE protein and mRNA illustrating the relative positions of all pathogenic mutations reported to date. Schematic representations.
Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration. Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration.

Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration. Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration.
Several microRNAs are differentially expressed in the glomeruli between different types of kidney disease. Several microRNAs are differentially expressed.

Several microRNAs are differentially expressed in the glomeruli between different types of kidney disease. Several microRNAs are differentially expressed.
INT-767 treatment regulates kidney bile acid composition, bile acid synthesis, and bile acid transporters in high-fat diet–induced obesity mice. INT-767.

INT-767 treatment regulates kidney bile acid composition, bile acid synthesis, and bile acid transporters in high-fat diet–induced obesity mice. INT-767.
INT-767 treatment prevents the increase in renal inflammation and oxidative stress in diabetic DBA/2J mice. INT-767 treatment prevents the increase in.

INT-767 treatment prevents the increase in renal inflammation and oxidative stress in diabetic DBA/2J mice. INT-767 treatment prevents the increase in.
INT-767 treatment prevents renal lipid accumulation in diabetic DBA/2J mice. INT-767 treatment prevents renal lipid accumulation in diabetic DBA/2J mice.

INT-767 treatment prevents renal lipid accumulation in diabetic DBA/2J mice. INT-767 treatment prevents renal lipid accumulation in diabetic DBA/2J mice.

Similar presentations

Ads by Google